Nymox Pharmaceutical Corporation (NYM.F)
Key Executives
Name | Title | Pay | Exercised | Year Born |
---|---|---|---|---|
Dr. Paul Averback DABP, M.D. | Founder, Chairman, CEO & President | 615.24k | -- | 1951 |
Ms. Lin Dodd | QA and Compliance Manager | -- | -- | -- |
Mr. Patrick Doody | VP, General Counsel & Director | -- | -- | -- |
Nymox Pharmaceutical Corporation
Description
Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population in Canada, the United States, Europe, and internationally. Its lead drug candidate is Fexapotide Triflutate (NX-1207), which is in various clinical trials for the treatment of benign prostatic hyperplasia and low grade localized prostate cancer, as well as is in preclinical studies for hepatocellular carcinoma. The company also develops and markets NicAlert for detecting tobacco product usage; and TobacAlert for detecting second-hand smoke exposure. In addition, it develops drugs for the treatment of Alzheimer's disease. Nymox Pharmaceutical Corporation was founded in 1989 and is headquartered in Nassau, the Bahamas.
Corporate Governance
Recent Events
- Mar 28, 20246-K: Corporate Changes & Voting MattersSee Full Filing
- Nov 15, 20236-K: Corporate Changes & Voting MattersSee Full Filing
- Nov 06, 20236-K: Corporate Changes & Voting MattersSee Full Filing
- Oct 26, 20236-K: Corporate Changes & Voting MattersSee Full Filing
- Sep 08, 202325-NSE: Notification filed by national security exchange to report the removal from listing and registration of maturedSee Full Filing
Upcoming Events
Upcoming Events Information Not Available